Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 6/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.41 |
| ▸ | TDP2 | O95551 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL654959 | 0.87 | ALDH1A1 (0.45) | ALDH1A1AKR1B1GAAPNMTADRA2A | |
| SCHEMBL28481900 | 0.80 | PNMT (0.44) | ALDH1A1AKR1B1GAAPNMTADRA2A | |
| SCHEMBL3604229 | 0.78 | BRD4 (0.53) | ALDH1A1AKR1B1GAAPNMTADRA2A | |
| SCHEMBL29059164 | 0.77 | TDP2 (0.55) | ALDH1A1PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL2061201 | 0.76 | TDP2 (0.47) | ALDH1A1AKR1B1GAAPNMTADRA2A | |
| SCHEMBL27150504 | 0.73 | MAPK1 (0.39) | ALDH1A1GAAMAPTSIRT6TSHR | |
| SCHEMBL29945643 | 0.73 | DPP7 (0.50) | ALDH1A1PNMTADRA2AADRA2BADRA2C | |
| SCHEMBL28804330 | 0.72 | AKR1B1 (0.43) | ALDH1A1AKR1B1TSHR | |
| SCHEMBL2100854 | 0.70 | KDM4E (0.41) | ALDH1A1GAAADRA2CMAPTRAB9A | |
| SCHEMBL3607837 | 0.70 | AKR1B1 (0.44) | ALDH1A1AKR1B1GAAPNMTADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3676255-B1 | THERAPEUTIC INDAZOLES | RUTGERS THE STATE UNIV UNIV OF NEW JERSEY (US) | 2025-04-16 | — | — | EP | disclosed |
| CN-111479805-B | Therapeutic indazoles | 罗格斯新泽西州立大学 | 2024-08-13 | — | — | CN | disclosed |
| US-12060330-B2 | Therapeutic indazoles | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2024-08-13 | — | — | US | disclosed |
| US-20220144781-A1 | THERAPEUTIC INDAZOLES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2022-05-12 | — | — | US | disclosed |
| US-11186549-B2 | Therapeutic indazoles | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2021-11-30 | — | — | US | disclosed |
| CN-111479805-A | Therapeutic indazoles | 罗格斯新泽西州立大学 | 2020-07-31 | — | — | CN | disclosed |
| EP-3676255-A1 | THERAPEUTIC INDAZOLES | Rutgers, The State University University Of New Jersey (US) | 2020-07-08 | — | — | EP | disclosed |
| US-20200199076-A1 | THERAPEUTIC INDAZOLES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-06-25 | — | — | US | disclosed |
| WO-2019046467-A1 | THERAPEUTIC INDAZOLES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-03-07 | — | — | WO | disclosed |
| EP-2316459-B1 | 2,4-pyrimidinediamine compounds for use in methods of treating or preventing autoimmune diseases | RIGEL PHARMACEUTICALS INC (US) | 2013-11-06 | — | — | EP | disclosed |
| US-8557806-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2013-10-15 | — | — | US | disclosed |
| US-8158621-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-7825116-B2 | -(2-Aminopyrid-6-yl)-5-fluoro-N2-[3-(N-methylamino)carbonylmethyleneoxyphenyl]-2,4-pyrimidinediamine; signal transduction cascade inhibitor; Fc receptors for immunoglobulins IgE and IgG antagonist; autoimmune diseases, antiinflammatory agent; rheumatoid arthritis, multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7812029-B1 | such as N4-[(2,2-Dimethyl-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine; Glomerulonephritis; rheumatoid arthritis; systemic lupus erythematosis; multiple sclerosis | RIGEL PHARMACEUTICALS, INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7517886-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060330-B2 | Therapeutic indazoles | RIF1, QTRT1, NQO2 | ALDH1A1 508/4885AKR1B1 666/4885GAA 2732/4885 |
| US-20220144781-A1 | THERAPEUTIC INDAZOLES | RIF1, QTRT1, NQO2 | ALDH1A1 508/4885AKR1B1 666/4885GAA 2732/4885 |
| US-20200199076-A1 | THERAPEUTIC INDAZOLES | RIF1, NQO2, QTRT1 | ALDH1A1 460/4885AKR1B1 647/4885GAA 2228/4885 |
| US-11186549-B2 | Therapeutic indazoles | RIF1, NQO2, QTRT1 | ALDH1A1 460/4885AKR1B1 647/4885GAA 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.